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ABSTRACT
Objective: To evaluate the safety and efficacy of intravenous and oral ofloxacin monotherapy in the
treatment of laparoscopically documented acute pelvic inflammatory disease (PID).
Methods: This study was conducted as an open-label, phase-III, uncontrolled, multicenter study.
Patients identified with laparoscopic findings of salpingitis were treated with 400 mg of intravenous
ofloxacin every 12 hours followed by 400 mg of oral ofloxacin every 12 hours for 10 to 14 days.
Patients were evaluated five times for clinical and microbial efficacy. Since laparoscopy was per-
formed only at admission, pathogens identified laparoscopically were presumed eradicated if they
were present on the laparoscopic culture and the patient was clinically cured or improved at final
evaluation.
Results: Of the 70 patients evaluable for safety (intent-to-treat population), the mean age was 25.6
years. Sixty-one of 70 patients (87%) were cured, one improved, one did not improve, and seven
were unevaluable because they discontinued study participation. Fifty-one were evaluable for clini-
cal efficacy: 50 (98%) were cured and one did not improve. Sixteen were evaluable for expanded
microbiological efficacy: three had documented Neisseria gonorrhoeae; 12, Chlamydia trachomatis;
and one, a mixed infection of both organisms. All cervical, laparoscopic, and endometrial cultured
pathogens, including N. gonorrhoeae and C. trachomatis, were eradicated or presumed eradicated at
the posttherapy visit. No serious or unexpected adverse events occurred.
Conclusions: Ofloxacin monotherapy was effective and well tolerated in the treatment of laparo-
scopically proven PID in a geographically diverse population. Future studies are necessary to
evaluate long-term outcomes and sequelae ofPID treatment with single agent therapy. Infect. Dis.
Obstet. Gynecol. 7:138-144, 1999. (C) 1999 Wiley-Liss, Inc.
KEY WORDS
fluoroquinolone; sexually transmitted disease; Neisseria gonorraoeae; Calamydia tracaomatis;
adnexitis; salpingitis
ver the past two decades, significant changes
have occurred in the accepted etiology, diag-
nosis, and treatment of acute pelvic inflammatory
disease (PID). Neisseria gonorrhoeae, once viewed as
the primary etiologic agent, is now one of several
microorganisms associated with PID. N. gonor-
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rhoeae, Chlamydia trachomatis, gram-negative enteric
bacteria, and pelvic anaerobes all have been iso-
lated from the upper genital tract of women diag-
nosed with acute PID. 1-4
Additionally, PID is often found to be a poly-
microbial infections with varying and complex pre-
sentations of signs and symptoms. Due to the prob-
ability of disease progression and the development
of serious long-term sequelae, immediate, treat-
ment of suspected PID with a broad-spectrum an-
tibiotic is recommended. To provide antimicrobial
activity against possible multiple pathogenic organ-
isms, the Centers for Disease Control and Preven-
tion (CDC) guidelines for the treatment of PID
recommend combination therapy regimens.6 For
oral treatment, these guidelines include the use of
the fluoroquinolone ofloxacin in combination with
metronidazole.
Ofloxacin has demonstrated in vitro activity
against N. gonorrhoeae (including penicillin-
resistant strains), C. trachomatis, gram-positive and
gram-negative aerobic bacteria, and some anaer-
obic bacteria. Additionally, it has been shown that
the pharmacokinetic properties of ofloxacin in-
clude high levels of drug distribution in gyneco-
logic tissues7 and 100% oral bioavailability, which
allows direct-dose conversion between parenteral
and oral therapy. The ability to eradicate a broad
spectrum of microorganisms and the ability to con-
vert directly from intravenous (IV) to oral admin-
istration enhance the clinical usefulness of ofloxa-
cin in the treatment of PID.
Soper et al. previously reported a clinical success
rate (cure plus improvement) of 100% for ofloxacin
monotherapy in the treatment of patients who had
N. gonorrhoeae as the dominant cause of PID.8 The
objective of our multicenter, open-label study was
to evaluate the safety and efficacy of IV and oral
ofloxacin monotherapy in the treatment of laparo-
scopically documented acute salpingitis in diverse
patient populations.
SUBJECTS AND METHODS
Women were eligible for participation if they had
clinical signs and symptoms consistent with a diag-
nosis of acute salpingitis (i.e., lower abdominal di-
rect tenderness, adnexal tenderness, and pain on
motion of cervix or uterus) plus one of the follow-
ing: oral temperature >38.3C, mucopurulent cer-
vical discharge, vaginal leukorrhea, elevated eryth-
rocyte sedimentation rate, or elevated C-reactive
protein. Exclusion criteria included women who
were lactating, currently pregnant, less than 18
years of age, postmenopausal, using an intrauterine
device, grossly underweight (40 kg), inappropriate
candidates for quinolone therapy, not suitable can-
didates for diagnostic laparoscopy, those who had
acquired immunodeficiency syndrome (AIDS),
tubo-ovarian abscess, active seizures, or major psy-
chiatric disorders, and those who had undergone
surgery for tubal ligation or hysterectomy. Patients
were also excluded from the study if they were
critically ill with conditions requiring immediate
surgery, had participated previously in this proto-
col, required concomitant systemic antimicrobial
therapy, or were exposed to any investigational
drug within the previous 30 days or to more than
one dose of any nontopical antimicrobial therapy
within the previous 48 hours. A geographically di-
verse study population was established by includ-
ing 71 patients from California, Florida, Illinois,
Louisiana, Pennsylvania, New York, and Rhode Is-
land. Prior to beginning the study protocol, Insti-
tutional Review Board approval was obtained at all
seven participating sites in the U.S. Before study
admittance, eligible patients signed an informed
consent form for participation.
To be evaluable, all women were required to
have documented laparoscopic evidence of salpin-
gitis (described below). Immediately following lap-
aroscopic confirmation, eligible patients were
treated with 400 mg of IV ofloxacin every 12 hours.
When an investigator determined that the patient
was able to tolerate oral medications, 400 mg of oral
ofloxacin was administered every 12 hours for a
total treatment duration (IV and oral medication) of
10 to 14 days.
Patients were evaluated at admission, 48 hours
after initiation of ofloxacin therapy, before conver-
sion to oral therapy, 3 to 15 days posttherapy (or at
early withdrawal), and 3 to 5 weeks after comple-
tion of therapy (long-term follow-up visit). Assess-
ment of clinical signs and symptoms at admission,
at 48 hours after the initiation of therapy, and at
both the posttherapy and long-term follow-up visit
included evaluation of abdominal pain, dysuria,
nausea/vomiting, fever, vaginal leukorrhea, and
mucopurulent cervical discharge. Physical exami-
nations and vital signs were recorded at admission,
48 hours after initiation of therapy, before conver-
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sion to oral therapy, and at posttherapy or early
withdrawal. Assessment ofPID included the estab-
lishment of a modified severity score based on the
method of McCormack et al.9 This PID severity
score was calculated by graded assessments (ab-
sent, minimal, moderate, and severe) of lower ab-
dominal direct tenderness, adnexal tenderness,
pain on motion of the cervix or uterus, and rebound
tenderness. Samples for serum chemistry, hematol-
ogy, and urinalysis were collected at admission, be-
fore conversion to oral therapy, and at the post-
therapy visit. Sexual history was reviewed at the
posttherapy and long-term visits.
In the current trial, a single laparoscopic exami-
nation at admission was used for the diagnosis of
acute salpingitis. The admission (pretreatment)
laparoscopic evaluation determined the presence
(or absence) of Fitz-Hugh-Curtis syndrome (i.e.,
presence of acute right upper quadrant pain and
tenderness in association with acute salpingitis)
and identified criteria specified by Westrom (Stu-
dent thesis, Lund, Sweden; 1976) as follows (1)
redness of fallopian tube surface, (2) edema of
tubal wall, and (3) purulent or seropurulent exu-
date covering tubal surface or leaking from fim-
briae. The severity of each Westrom criterion was
rated as none, mild, moderate, or severe by the
investigator. Patients were considered to have lapa-
roscopically documented acute salpingitis if (1) all
three Westrom criteria were present or (2) at least
one Westrom criterion was present combined with
a positive admission culture of N. gonorrhoeae and/
or C. trachomatis from either the laparoscopically
obtained or endometrial biopsy specimens. This
definition was chosen to maximize the sensitivity
(minimizing the occurrence of false negatives) of
laparoscopic evaluations.1
Clinical response was determined by the inves-
tigator 3 to 15 days following completion of ofloxa-
cin therapy. Clinical response was assessed as ei-
ther cured, improved, failed (no improvement), or
unable to evaluate.
To determine microbiological efficacy, samples
for culture from the cervix and endometrium were
obtained at admission and during laparoscopy from
a fallopian tube puncture or fimbrial exudate. For
this study, pathogens were defined as isolates of N.
gonorrhoeae and C. trachomatis. In addition, all iso-
lated aerobic organisms, with the exception of C.
trachomatis, were tested according to the National
Committee for Clinical Laboratory Standards
(NCCLS) disk susceptibility protocol, aa and all or-
ganisms (aerobes and anaerobes) were evaluated
per NCCLS minimum inhibitory concentration
(MIC) determination protocols, lz,13
All culture samples also were analyzed for C.
trachomatis by a polymerase chain reaction (PCR)
assay. Repeat culture samples for C. trachomatis
only were obtained from the cervix and, if positive
at admission, from the endometrium during the
posttherapy and long-term visits.
In vivo microbiological response to ofloxacin
therapy was determined for N. gonorrhoeae and C.
trachomatis. Positive admission endometrial and
cervical culture results were compared to culture
results obtained from same-site samples collected
during the posttherapy visit. Microbiological re-
sponse for endometrial and cervical culture results
was assessed as eradicated, persisted, new infection
(i.e., new pathogen present), or unable to evaluate.
Since laparoscopy was performed only at admis-
sion, only presumed microbiological response
based on clinical response could be determined for
laparoscopically isolated pathogens. If a pathogen
was present at laparoscopy and the patient was
clinically cured or improved at the posttherapy
visit, the organism was presumed to be eradicated.
Similarly, if the patient was assessed as a clinical
failure posttherapy, any laparoscopically obtained
pathogen was presumed to have persisted.
Additionally, all patients who received at least
one dose of ofloxacin (intent-to-treat population)
were evaluated for safety throughout the entire
study (up to 5 weeks posttherapy). All adverse
events were documented by the investigator and
assessed as mild, moderate, or marked. The rela-
tionship of adverse event to study drug also was
assessed by the investigator as none, unlikely, pos-
sible, probable/likely, or certain.
Efficacy parameters were summarized and tabu-
lated without any inferential statistical analysis. Vi-
tal signs (oral temperature, respiratory rate, pulse
rate, and systolic and diastolic blood pressure) were
compared using the Student paired t test (two-
tailed) to test the null hypothesis that the means of
the vital sign measurements at admission and post-
therapy were equal. The changes in laboratory test
results (hematology, blood chemistry, and urinaly-
sis tests) were analyzed using a modified McNemar
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statistical test14 based on the chi-square distribu-
tion with one degree of freedom and a correction
of continuity. The test was based on changes in
investigator-supplied normal ranges. All statistical
inferences were based on type-I error rate of 0.05.
All statistical appendices and tabulations were gen-
erated using the Statistical Analysis System
(SAS).1
TABLE I. Anaerobic bacteria isolated from the
endometrium at admission








A total of 70 patients received at least one dose of
ofloxacin and were evaluated for safety. Sixty-two
patients (89%) had the diagnosis of acute PID con-
firmed at laparoscopy. Nineteen of the 70 patients
were excluded from the analysis of clinical efficacy:
10 were excluded due to protocol violations, eight
patients had a negative laparoscopic evaluation,
and one patient did not have a final assessment.
Fifty-one patients were therefore evaluable for
clinical efficacy. Seven patients were considered
microbiologically evaluable based on positive cul-
tures for N. gonorrhoeae or C. trachornatis from lapa-
roscopic and/or endometrial specimens at admis-
sion. Sixteen patients were evaluable for expanded
microbiological efficacy based on cultures from lap-
aroscopic, endometrial, or cervical specimens.
Of the clinically evaluable study population (N
51), 24% were white and 63% were black, and the
mean age was 25.1 years. On admission, 50 patients
(98%) reported abdominal pain, 27 (53%) had nau-
sea/vomiting, and 19 (37%) had dysuria. Mucopu-
rulent cervical discharge was noted in 42 (82%),
and 38 (75%) had leukorrhea. Three patients (6%)
had a temperature above 38.5C and 11 patients
(22%) had an abnormal white blood cell count
(-> 15,000 or <5,000). Eighteen patients (35%) were
noted to have Fitz-Hugh-Curtis syndrome on lap-
aroscopic evaluation. Microbiological results were
as follows: 16 patients (31%) had positive cultures
for N. gonorrhoeae and/or C. trachomatis, 20 (39%)
had positive cultures for other organisms, and 15
(29%) had negative culture results. Six types of
anaerobic bacteria were isolated from the endome-
trium a total of 13 times (Table 1).
The mean number of days of IV ofloxacin
therapy was 2.3 prior to conversion to oral therapy.
The mean number of treatment days for both regi-
mens (IV and oral) was 13.6 (range: 9 to 16.5 days).
At the posttherapy visit 50 of the 51 clinically
evaluable patients with a history of PID (98%)
were assessed as clinically cured. One patient had
negative culture and PCR determinations at admis-
sion and was considered a treatment failure at the
3- to 15-day posttreatment evaluation. In accor-
dance with a protocol provision, this patient re-
mained on ofloxacin therapy with the addition of
metronidazole and was subsequently cured of her
current episode of PID.
Patients who were clinically evaluable at 3-15
days posttherapy had significant improvement in
PID signs and symptoms. At admission, abdominal
pain, nausea/vomiting, and dysuria, were present in
98%, 53%, and 37%, respectively. Posttherapy, 4%
(2/51) had abdominal pain, 8% (4/51) had nausea/
vomiting, and 4% (2/51) had dysuria. Those symp-
toms that were present posttherapy were mild in
severity, with the exception of one case of severe
dysuria. Scores ofPID also showed improvement at
posttherapy. At admission, 31 patients (61%) had a
PID score of at least 7, and 20 patients (39%) had
a score between and 6. At the posttherapy visit,
47 patients (92%) who were clinically evaluable
had a PID score of 0, and 4 (8%) had a residual PID
score of to 3, indicating minimal persistence of a
single symptom. Of these 4, the one patient with a
residual McCormack PID score of 3 was considered
a clinical failure.
In order to assess any relapse or reinfection, the
severity of signs and symptoms present at admis-
sion was compared to the severity of signs and
symptoms persisting 3 to 5 weeks posttherapy. The
efficacy of ofloxacin was confirmed by the transi-
tion of signs and symptoms at the long-term visit,
where there was no clinical evidence of relapse or
reinfection. Among the clinically evaluable popu-
lation, 90% or more had no signs or symptoms of
pain, dysuria, mucopurulent cervical discharge,
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vaginal leukorrhea, or nausea and/or vomiting. The
only reported signs and symptoms present at long-
term follow up that were not present on admission
were two instances of mild-to-moderate dysuria
and one report of mild nausea and vomiting.
Among 51 clinically evaluable patients, three
had documented infection due to N. gonorrhoeae, 12
had documented infection due to C. trachomatis,
and one had a mixed infection due to both organ-
isms. As expected, the initial site of these patho-
gens varied. C. trachomatis alone was isolated in 12
patients at the following sites: cervix (8); cervix and
endometrium (1); cervix and at laparoscopy (1); and
cervix, endometrium, and at laparoscopy (2). N.
gonorrhoeae alone was isolated in three patients at
the following initial sites: cervix (1); endometrium
(1); and cervix, endometrium, and at laparoscopy
(1). Additionally, one patient had a cervical culture
positive for both C. trachomatis and N. gonorrhoeae
coupled with an endometrial culture positive only
for N. gonorrhoeae. In 16 microbiologically evaluable
patients with organisms from laparoscopic, endo-
metrial, and/or cervical specimens isolated at ad-
mission, all N. gonorrhoeae and C. trachomatis organ-
isms were eradicated or presumed eradicated at the
3- to 15-day posttherapy evaluation. Furthermore,
six anaerobic organisms were isolated from 13 pa-
tients (see Table 1), primarily from the endometri-
al sites, at admission. At the posttherapy visit, all
patients with anaerobic isolates identified at admis-
sion were considered clinically cured.
In vitro ofloxacin susceptibility testing was per-
formed on all organisms isolated at admission, with
the exception of C. trachomatis. These data include
all patients who were not clinically evaluable. N.
gonorrhoeae was isolated nine times: seven isolates
were susceptible to ofloxacin, and two had no data
reported. Twenty-two other organisms were iso-
lated 55 times: 25 isolates were susceptible to
ofloxacin, three had intermediate susceptibility,
three were resistant, and 24 had no susceptibility
results (see Table 2).
A long-term follow-up visit was not required for
completion of the study; however, efforts were
made 3 to 5 weeks posttherapy to obtain patient
culture specimens from cervical and endometrial
sites. Sixteen patients who had pathogens isolated
at admission showed negative cervical and/or en-
dometrial cultures for C. trachomatis and N. gonor-
rhoeae at the long-term follow-up visit. N. gonor-
TABLE 2. In vitro ofloxacin susceptability
at admission
Intermediate




























aln vitro susceptibility testing was performed on all organisms isolated
at admission except C. trachomatis. N. gonorrhoeae was isolated nine
times: seven isolates were susceptible to ofloxacin, and two had no data
reported.
rhoeae was not present among patients at the long-
term follow-up evaluation. One patient with a
positive cervical culture only for N. gonorrhoeae at
admission was found to have a positive cervical
culture only for C. trachomatis at the long-term fol-
low-up evaluation. At the 3- to 15-day posttherapy
visit, however, this patient had a negative cervical
culture for both organisms and was assessed as mi-
crobiologically cured. This patient had resumed
unprotected sexual activity after the 3- to 15-day
posttherapy visit; thus, the long-term follow-up
positive cervical culture for C. trachomatis may have
been due to a new sexually transmitted infection.
Of the 70 patients evaluable for safety, 17 (24%)
reported at least one adverse event related to the
study drug. No deaths or serious adverse events
occurred during the study. The most common side
effect was a reported fungal infection experienced
by 11 patients (15.7%). Seven patients (10%) ex-
perienced nausea. Two patients (3%) experienced
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a nervous system complaint, and one (1.4%) expe-
rienced a dermatologic complaint.
DISCUSSION
Ofloxacin monotherapy is reported to be as effec-
tive as the traditional therapy of cefoxitin and
doxycycline for the treatment of PID. Results from
two comparative studies of women with PID
showed a clinical success rate (cured plus improved
patients) for ofloxacin monotherapy of 95% in a
total of 165 patients, compared with clinical success
rates of 93% to 97% reported among 156 patients
treated with cefoxitin and doxycycline. 16,17 Consis-
tent with these findings, a noncomparative double
laparoscopic study of 36 patients treated with
ofloxacin showed a 100% clinical success rate.8
This clinical evaluation of 70 patients with di-
verse demographic and geographic characteristics
supports the previously reported findings regarding
the use of ofloxacin as monotherapy for the treat-
ment of acute PID. Although this was an uncon-
trolled study, of the 51 clinically evaluable patients,
50 (98%) were clinically cured after ofloxacin treat-
ment. The one patient assessed as a clinical failure
had a prior history of Chlamydia-associated PID;
however, her pathogen culture and PCR results
were negative at admission. This patient was clini-
cally cured with continued ofloxacin therapy and
the addition of metronidazole in accordance with
the protocol.
Microbiological response to ofloxacin treatment
for the 16 patients with cultures positive for N.
gonorrhoeae and/or C. trachomatis was 100% eradi-
cated (confirmed or presumed) at 3 to 15 days post-
therapy. These results are comparable to other
well-controlled studies of ofloxacin treatment in
women with PID, which have reported 100% eradi-
cation of N. gonorrhoeae and 86 to 100% eradication
of C. trachomatis.8,6,7 Sites of pathogens at admis-
sion were consistent with other studies in that the
majority of pathogens (9 of 16) were isolated from
the cervix. However, the percentage of patients
(31%) with both laparoscopically documented sal-
pingitis and culture findings positive for these or-
ganisms was significantly lower than previously re-
ported. This difference may be due to the geo-
graphically diverse patient population or a possible
high prevalence of women with PID due to rein-
fection by undetectable levels of C. trachomatis.
Soper et al., who reported on a more geographically
homogeneous population, found isolation ofN. gon-
orrhoeae and/or C. trachomatis in 31 (86%) of 36 pa-
tients with laparoscopically documented salpingi-
tis.8
In this study, seven isolates of the pathogen N.
gonorrhoeae and 25 isolates of other aerobic and an-
aerobic organisms were susceptible to ofloxacin
(see Table 2). Additionally, 13 anaerobic isolates
were identified (see Table 1). One isolate of Pep-
tostreptococcus anaerobius and one Bacteroides isolate
were susceptible to ofloxacin. Three Bacteroides
isolates had unknown sensitivities (not tested).
The three Bacteroides fragilis isolates had an inter-
mediate susceptibility to ofloxacin. Therefore, of
the five anaerobic isolates tested, all were suscep-
tible to ofloxacin; no anaerobes were found to be
resistant. Prevotella was not isolated from any pa-
tient in this study.
The high clinical cure rate of ofloxacin in this
study, combined with the in vitro studies, suggests
that ofloxacin is effective in curing PID caused by
multiple pathogens, including possible anaerobic
pathogens. This successful outcome may be due to
the high concentration of ofloxacin in the gyneco-
logic tissues during treatment. 7 However, this
study did not have a long-term follow-up period to
determine whether treatment prevented long-term
sequelae. If the anaerobic organisms are not com-
pletely eradicated, they may persist and increase
the risk of relapses. As has been shown in the study
by Sweet et al., some patients treated for acute
salpingitis have persistent chlamydial infection de-
spite apparent clinical cure, which might cause
chronic fallopian tube infection.8 A separate con-
cern raised by some authorities is that a 14-day
course of quinolone therapy may select for quino-
lone-resistant Pseudomonas species.
With respect to the safety evaluation, no deaths
or serious adverse events occurred. The type and
incidence of adverse events that were noted did
not differ significantly from what has been previ-
ously associated with ofloxacin treatment.
In conclusion, this study supports an accumulat-
ing body of evidence that ofloxacin monotherapy is
a safe and effective treatment for acute salpingitis.
With the addition of this study to the medical lit-
erature, clinical success rates of 95% to 100% have
been achieved with ofloxacin monotherapy for the
treatment of PID in more than 250 clinically evalu-
able patients. Based on these findings, a 10- to
INFECTIOUS DISEASES 1N OBSTETRICS AND GYNECOLOGY 143OFLOXACINMONOTHERAPYFOR PID PEIPERTET AL.
14-day treatment of IV ofloxacin with conversion
after approximately 2 days to oral therapy is effec-
tive in the treatment of laparoscopically docu-
mented acute salpingitis. Additionally, ofloxacin, as
either an IV or oral formulation, is generally safe
and well tolerated in women being treated for
acute PID. Additional studies, however, are
needed to determine if persistent pathogens will
present a clinical problem, and if long-term out-
comes are similar in patients treated with ofloxacin
or other standard therapies.
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